Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | Director | October 01, 2026 | October 02, 2026 |
| Zymeworks BC Inc.ZYME · Entity 12038 | Director | May 06, 2021 | May 07, 2021 |
| Zymeworks Inc.ZYME · Entity 4458 | Director | December 07, 2023 | December 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,995 |
Ending reported balance
After 2026-10-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 5,000 · Balance 15,995 Row 2 · 2026-10-01 · Sale · Disposed 5,000 · Balance 10,995 F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.435 to $50.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $18.03 · Expires 2027-02-23 | Direct | 10,000 |
Reported balance
After 2026-10-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-01 · Exercise / conversion · Disposed 5,000 · Balance 10,000 F3: The stock option is fully vested and exercisable. F4: In addition to the remaining options to purchase 10,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 92,320 shares of common stock, which options vest according to their terms. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.435 to $50.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The stock option is fully vested and exercisable.
F4: In addition to the remaining options to purchase 10,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 92,320 shares of common stock, which options vest according to their terms.
Zymeworks BC Inc.
Report date May 06, 2021 · Filed May 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.49 · Expires 2031-05-05 | Direct | 9,000 |
Reported balance
After 2021-05-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-06 · Grant · Acquired 9,000 · Balance 9,000 F1: Stock options vest on date of next annual general meeting following grant date of May 6, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on date of next annual general meeting following grant date of May 6, 2021.
Zymeworks Inc.
Report date December 07, 2023 · Filed December 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.55 · Expires 2033-12-06 | Direct | 37,000 |
Reported balance
After 2023-12-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-12-07 · Grant · Acquired 37,000 · Balance 37,000 F1: Stock options vest on date of next annual general meeting following grant date of December 7, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on date of next annual general meeting following grant date of December 7, 2023.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CEPHEID
Report date November 04, 2016 · Filed November 07, 2016
Section 16 reporting ended · disclosed 2016-11-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2016-11-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2016-10-31 · Gift · Disposed 3,350 · Balance 11,567 Row 2 · 2016-11-04 · Disposition to issuer · Disposed 11,567 · Balance 0 F1: This number includes RSUs previously reported on Table I that at closing, were accelerated and converted into the right to receive $53 per share, without interest. F2: On September 2, 2016, the Issuer entered into an Agreement and Plan of Merger ("Merger Agreement") with Danaher Corporation, a Delaware corporation (the "Acquirer"), and Copper Merger Sub, Inc., a California corporation and a wholly-owned subsidiary of the Acquirer. Upon the closing of the transactions contemplated by the Merger Agreement on November 4, 2016 (the "Closing"), each of the Reporting Person's shares of the Issuer's Common Stock was cancelled and converted into the right to receive $53.00, without interest (the "Merger Consideration"). |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.72 · Expires 2019-04-24 | Direct | 0 |
Reported balance
After 2016-11-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-11-04 · Disposition to issuer · Disposed 7,800 · Balance 0 F3: Upon the Closing, 100% of these options were cancelled and converted into the right to receive an amount of cash equal to the number of shares outstanding under this option multiplied by $53 minus the option exercise price. F4: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.13 · Expires 2020-04-30 | Direct | 0 |
Reported balance
After 2016-11-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-11-04 · Disposition to issuer · Disposed 7,800 · Balance 0 F3: Upon the Closing, 100% of these options were cancelled and converted into the right to receive an amount of cash equal to the number of shares outstanding under this option multiplied by $53 minus the option exercise price. F4: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.59 · Expires 2021-04-22 | Direct | 0 |
Reported balance
After 2016-11-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2016-11-04 · Disposition to issuer · Disposed 16,300 · Balance 0 F3: Upon the Closing, 100% of these options were cancelled and converted into the right to receive an amount of cash equal to the number of shares outstanding under this option multiplied by $53 minus the option exercise price. F4: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.70 · Expires 2022-04-28 | Direct | 0 |
Reported balance
After 2016-11-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2016-11-04 · Disposition to issuer · Disposed 16,300 · Balance 0 F5: Upon the Closing, this option was cancelled and ceased to exist without receiving any payment therefor. F4: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.59 · Expires 2023-04-26 | Direct | 0 |
Reported balance
After 2016-11-04 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2016-11-04 · Disposition to issuer · Disposed 16,300 · Balance 0 F6: Upon the Closing, 100% of this option's vesting was accelerated and converted into the right to receive an amount of cash equal to the number of shares outstanding under the option multiplied by $53.00 minus the exercise price. F4: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This number includes RSUs previously reported on Table I that at closing, were accelerated and converted into the right to receive $53 per share, without interest.
F2: On September 2, 2016, the Issuer entered into an Agreement and Plan of Merger ("Merger Agreement") with Danaher Corporation, a Delaware corporation (the "Acquirer"), and Copper Merger Sub, Inc., a California corporation and a wholly-owned subsidiary of the Acquirer. Upon the closing of the transactions contemplated by the Merger Agreement on November 4, 2016 (the "Closing"), each of the Reporting Person's shares of the Issuer's Common Stock was cancelled and converted into the right to receive $53.00, without interest (the "Merger Consideration").
F3: Upon the Closing, 100% of these options were cancelled and converted into the right to receive an amount of cash equal to the number of shares outstanding under this option multiplied by $53 minus the option exercise price.
F4: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date.
F5: Upon the Closing, this option was cancelled and ceased to exist without receiving any payment therefor.
F6: Upon the Closing, 100% of this option's vesting was accelerated and converted into the right to receive an amount of cash equal to the number of shares outstanding under the option multiplied by $53.00 minus the exercise price.
PORTOLA PHARMACEUTICALS INC
Report date July 02, 2020 · Filed July 02, 2020
Section 16 reporting ended · disclosed 2020-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 1
1 source rowRow 1 · 2020-07-02 · Disposition to issuer · Disposed 13,194 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | IndirectThe Renton Family Community Property Trust | 0 |
Reported balance
After 2020-07-02 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-07-02 · Disposition to issuer · Disposed 2,826 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes. |
| Restricted Stock UnitsSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 3
1 source rowRow 3 · 2020-07-02 · Disposition to issuer · Disposed 7,281 · Balance 0 F2: At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.94 · Expires 2030-06-11 | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-07-02 · Disposition to issuer · Disposed 11,377 · Balance 0 F3: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-07-02 · Disposition to issuer · Disposed 59,092 · Balance 0 F4: In connection with the Merger, these options were accelerated and canceled without payment. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.
F2: At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00.
F3: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.
F4: In connection with the Merger, these options were accelerated and canceled without payment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2024 Filed Jan 5, 2024 21:56 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001048 · doc4.xml · derivative · entry 2 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,030 Underlying: Common Stock · 6,030 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 21:56 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 16,510 | $0.00 Strike: $21.19 | $0.00 |
DisclosureSEC source: 0001209191-24-001048 · doc4.xml · derivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,510 Underlying: Common Stock · 16,510 shares Expires 2034-01-02 F1 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on Februray 3, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| December 07, 2023 Filed Dec 8, 2023 22:41 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 37,000 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0000950170-23-069121 · ownership.xml · derivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 37,000 shares Expires 2033-12-06 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of December 7, 2023. Read SEC document |
| January 06, 2023 Filed Jan 11, 2023 00:10 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 3,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002884 · doc4.xml · derivative · entry 2 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,900 Underlying: Common Stock · 3,900 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2023 Filed Jan 11, 2023 00:10 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 10,600 | $0.00 Strike: $23.23 | $0.00 |
DisclosureSEC source: 0001209191-23-002884 · doc4.xml · derivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,600 Underlying: Common Stock · 10,600 shares Expires 2033-01-05 F1 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2023 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| December 21, 2022 Filed Dec 24, 2022 00:00 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $8.75 | $0.00 |
DisclosureSEC source: 0000899243-22-039321 · doc4.xml · derivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-12-20 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of December 21, 2022. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:48 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 9,200 | $0.00 Strike: $30.44 | $0.00 |
DisclosureSEC source: 0001209191-22-009339 · doc4.xml · derivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,200 Underlying: Common Stock · 9,200 shares Expires 2032-02-09 F1 · derivative.exercise_date: The stock option vests as of 1/12 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| May 06, 2021 Filed May 7, 2021 20:45 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $29.49 | $0.00 |
DisclosureSEC source: 0000899243-21-018763 · doc4.xml · derivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Shares · 9,000 shares Expires 2031-05-05 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of May 6, 2021. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 02:44 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $29.70 | $0.00 |
DisclosureSEC source: 0001209191-21-010534 · doc4.xml · derivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2031-02-09 F1 · derivative.exercise_date: The stock option vests as of 1/12 of the total shares monthly beginning on March 10, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| July 02, 2020 Filed Jul 2, 2020 16:38 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerStock Option (Right to Buy) · Derivative | 59,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-040364 · doc4.xml · derivative · entry 5 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 59,092 shares Expires not disclosed F4 · derivative.exercise_price: In connection with the Merger, these options were accelerated and canceled without payment. F4 · price: In connection with the Merger, these options were accelerated and canceled without payment. F4 · derivative.exercise_date: In connection with the Merger, these options were accelerated and canceled without payment. F4 · derivative.expiration_date: In connection with the Merger, these options were accelerated and canceled without payment. Read SEC document |
| July 02, 2020 Filed Jul 2, 2020 16:38 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerStock Option (Right to Buy) · Derivative | 11,377 | $0.06 Strike: $17.94 | $682.62 |
DisclosureSEC source: 0001209191-20-040364 · doc4.xml · derivative · entry 4 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,377 shares Expires 2030-06-11 F3 · price: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. F3 · derivative.exercise_date: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. Read SEC document |
| July 02, 2020 Filed Jul 2, 2020 16:38 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerRestricted Stock Units | 7,281 | $18.00 | $131,058.00 |
DisclosureSEC source: 0001209191-20-040364 · doc4.xml · nonDerivative · entry 3 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · acquired: At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00. Read SEC document |
| July 02, 2020 Filed Jul 2, 2020 16:38 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerCommon Stock | 2,826 | $18.00 | $50,868.00 |
DisclosureSEC source: 0001209191-20-040364 · doc4.xml · nonDerivative · entry 2 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Renton Family Community Property Trust Disclosed balance after: 0 F1 · acquired: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes. Read SEC document |
| July 02, 2020 Filed Jul 2, 2020 16:38 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerCommon Stock | 13,194 | $18.00 | $237,492.00 |
DisclosureSEC source: 0001209191-20-040364 · doc4.xml · nonDerivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · acquired: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes. Read SEC document |
| June 12, 2020 Filed Jun 15, 2020 19:10 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantStock Option (Right to Buy) · Derivative | 11,377 | $0.00 Strike: $17.94 | $0.00 |
DisclosureSEC source: 0001209191-20-036781 · doc4.xml · derivative · entry 3 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,377 Underlying: Common Stock · 11,377 shares Expires 2030-06-11 F2 · derivative.exercise_date: The Option shall vest as follows: 1/12th of the shares subject to the option shall vest on the first of each month after the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. Read SEC document |
| June 12, 2020 Filed Jun 15, 2020 19:10 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantCommon Stock | 7,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036781 · doc4.xml · nonDerivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,475 F1 · shares: Grant of Restricted Stock Units ("RSUs") in consideration of services rendered. The RSUs fully vest on March 1, 2021, subject to the Reporting Person's Continuous Services (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date. Read SEC document |
| May 08, 2020 Filed May 12, 2020 06:30 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $35.49 | $0.00 |
DisclosureSEC source: 0000899243-20-012773 · doc4.xml · derivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Shares · 9,000 shares Expires 2030-05-07 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of May 8, 2020. Read SEC document |
| February 12, 2020 Filed Feb 13, 2020 22:07 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantDirector Stock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $16.56 | $0.00 |
DisclosureSEC source: 0001209191-20-009322 · doc4.xml · derivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2030-02-11 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 12, 2020, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 19:32 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionStock Options (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001209191-19-055045 · doc4.xml · derivative · entry 4 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2020-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2019. F2 · derivative.exercise_date: The option, representing a right to purchase a total of 20,000 shares, became exercisable monthly over a two year period beginning on May 29, 2010. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 19:32 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | SaleCommon Stock | 5,000 | $30.00 | $150,000.00 |
DisclosureSEC source: 0001209191-19-055045 · doc4.xml · nonDerivative · entry 2 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,194 F1 · shares: The sale reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2019. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 19:32 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionCommon Stock | 5,000 | $9.00 | $45,000.00 |
DisclosureSEC source: 0001209191-19-055045 · doc4.xml · nonDerivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2019. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 18:51 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionStock Options (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001209191-19-045396 · doc4.xml · derivative · entry 4 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires 2020-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2019. F2 · derivative.exercise_date: The option, representing a right to purchase a total of 20,000 shares, became exercisable monthly over a two year period beginning on May 29, 2010. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 18:51 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | SaleCommon Stock | 5,000 | $30.00 | $150,000.00 |
DisclosureSEC source: 0001209191-19-045396 · doc4.xml · nonDerivative · entry 2 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,194 F1 · shares: The sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2019. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 18:51 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionCommon Stock | 5,000 | $9.00 | $45,000.00 |
DisclosureSEC source: 0001209191-19-045396 · doc4.xml · nonDerivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2019. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 17:33 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantStock Option (Right to Buy) · Derivative | 6,991 | $0.00 Strike: $26.09 | $0.00 |
DisclosureSEC source: 0001209191-19-037464 · doc4.xml · derivative · entry 3 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,991 Underlying: Common Stock · 6,991 shares Expires 2029-06-12 F2 · derivative.exercise_date: The Option shall vest as follows: 1/12th of the shares subject to the option shall vest on the first of each month after the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 17:33 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantCommon Stock | 4,194 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-037464 · doc4.xml · nonDerivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,194 F1 · shares: Grant of Restricted Stock Units ("RSUs") in consideration of services rendered. The RSUs fully vest on March 1, 2020, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date. Read SEC document |
| May 06, 2019 Filed May 8, 2019 16:21 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $19.11 | $0.00 |
DisclosureSEC source: 0000899243-19-012636 · doc4.xml · derivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2029-05-05 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of May 6, 2019. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 19:44 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionStock Options (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001209191-19-024839 · doc4.xml · derivative · entry 5 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 5,000 shares Expires 2020-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2019. F4 · derivative.exercise_date: The option, representing a right to purchase a total of 20,000 shares, became exercisable monthly over a two year period beginning on May 29, 2010. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 19:44 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | SaleCommon Stock | 400 | $35.07 | $14,027.00 |
DisclosureSEC source: 0001209191-19-024839 · doc4.xml · nonDerivative · entry 3 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2019. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.0000 to $35.1800, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) - (3) to this Form 4. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 19:44 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | SaleCommon Stock | 4,600 | $34.40 | $158,222.52 |
DisclosureSEC source: 0001209191-19-024839 · doc4.xml · nonDerivative · entry 2 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,400 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2019. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.9700 to $34.9650, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) - (3) to this Form 4. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 19:44 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionCommon Stock | 5,000 | $9.00 | $45,000.00 |
DisclosureSEC source: 0001209191-19-024839 · doc4.xml · nonDerivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2019. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 22:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantDirector Stock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $68.89 | $0.00 |
DisclosureSEC source: 0001209191-19-009036 · doc4.xml · derivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2019-02-07 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 8, 2019, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 08, 2018 Filed Jun 8, 2018 18:42 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $42.81 | $0.00 |
DisclosureSEC source: 0001209191-18-036778 · doc4.xml · derivative · entry 3 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-06-07 F2 · derivative.exercise_date: The Option shall vest as follows: 1/12th of the shares subject to the option shall vest on the first of each month after the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. Read SEC document |
| June 08, 2018 Filed Jun 8, 2018 18:42 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-036778 · doc4.xml · nonDerivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 F1 · shares: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSUs fully vest on March 1, 2019, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date. Read SEC document |
| February 02, 2018 Filed Feb 6, 2018 21:13 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantDirector Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $104.81 | $0.00 |
DisclosureSEC source: 0001209191-18-007832 · doc4.xml · derivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-02-01 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 2, 2018, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 16, 2017 Filed Jun 19, 2017 18:14 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $35.06 | $0.00 |
DisclosureSEC source: 0001209191-17-040923 · doc4.xml · derivative · entry 2 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2027-06-16 F2 · derivative.exercise_date: The Option shall vest as follows: 1/12th of the shares subject to the option shall vest each month after June 1, 2017, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. Read SEC document |
| June 16, 2017 Filed Jun 19, 2017 18:14 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040923 · doc4.xml · nonDerivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · shares: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSUs fully vest on March 1, 2018, subject to Reporting Person's Continuous Service as of each such date. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 23:55 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantDirector Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $24.60 | $0.00 |
DisclosureSEC source: 0001209191-17-015461 · doc4.xml · derivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-02-23 F1 · derivative.exercise_date: The stock option vests and becomes fully exercisable on February 24, 2018. Read SEC document |
| November 04, 2016 Filed Nov 7, 2016 19:37 UTC | CEPHEID CPHD · Entity 181259 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 16,300 | $0.00 Strike: $36.59 | $0.00 |
DisclosureSEC source: 0001209191-16-148750 · doc4.xml · derivative · entry 7 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,300 shares Expires 2023-04-26 F6 · shares: Upon the Closing, 100% of this option's vesting was accelerated and converted into the right to receive an amount of cash equal to the number of shares outstanding under the option multiplied by $53.00 minus the exercise price. F4 · derivative.exercise_date: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date. Read SEC document |
| November 04, 2016 Filed Nov 7, 2016 19:37 UTC | CEPHEID CPHD · Entity 181259 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 16,300 | $0.00 Strike: $56.70 | $0.00 |
DisclosureSEC source: 0001209191-16-148750 · doc4.xml · derivative · entry 6 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,300 shares Expires 2022-04-28 F5 · shares: Upon the Closing, this option was cancelled and ceased to exist without receiving any payment therefor. F4 · derivative.exercise_date: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date. Read SEC document |
| November 04, 2016 Filed Nov 7, 2016 19:37 UTC | CEPHEID CPHD · Entity 181259 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 16,300 | $0.00 Strike: $45.59 | $0.00 |
DisclosureSEC source: 0001209191-16-148750 · doc4.xml · derivative · entry 5 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,300 shares Expires 2021-04-22 F3 · shares: Upon the Closing, 100% of these options were cancelled and converted into the right to receive an amount of cash equal to the number of shares outstanding under this option multiplied by $53 minus the option exercise price. F4 · derivative.exercise_date: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date. Read SEC document |
| November 04, 2016 Filed Nov 7, 2016 19:37 UTC | CEPHEID CPHD · Entity 181259 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $38.13 | $0.00 |
DisclosureSEC source: 0001209191-16-148750 · doc4.xml · derivative · entry 4 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,800 shares Expires 2020-04-30 F3 · shares: Upon the Closing, 100% of these options were cancelled and converted into the right to receive an amount of cash equal to the number of shares outstanding under this option multiplied by $53 minus the option exercise price. F4 · derivative.exercise_date: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date. Read SEC document |
| November 04, 2016 Filed Nov 7, 2016 19:37 UTC | CEPHEID CPHD · Entity 181259 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $35.72 | $0.00 |
DisclosureSEC source: 0001209191-16-148750 · doc4.xml · derivative · entry 3 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,800 shares Expires 2019-04-24 F3 · shares: Upon the Closing, 100% of these options were cancelled and converted into the right to receive an amount of cash equal to the number of shares outstanding under this option multiplied by $53 minus the option exercise price. F4 · derivative.exercise_date: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date. Read SEC document |
| November 04, 2016 Filed Nov 7, 2016 19:37 UTC | CEPHEID CPHD · Entity 181259 | Disposition to issuerCommon Stock | 11,567 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-148750 · doc4.xml · nonDerivative · entry 2 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: This number includes RSUs previously reported on Table I that at closing, were accelerated and converted into the right to receive $53 per share, without interest. F2 · price: On September 2, 2016, the Issuer entered into an Agreement and Plan of Merger ("Merger Agreement") with Danaher Corporation, a Delaware corporation (the "Acquirer"), and Copper Merger Sub, Inc., a California corporation and a wholly-owned subsidiary of the Acquirer. Upon the closing of the transactions contemplated by the Merger Agreement on November 4, 2016 (the "Closing"), each of the Reporting Person's shares of the Issuer's Common Stock was cancelled and converted into the right to receive $53.00, without interest (the "Merger Consideration"). Read SEC document |
| October 31, 2016 Filed Nov 7, 2016 19:37 UTC | CEPHEID CPHD · Entity 181259 | GiftCommon Stock | 3,350 | $52.90 | $177,215.00 |
DisclosureSEC source: 0001209191-16-148750 · doc4.xml · nonDerivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,567 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.